Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Croatia Pharmaceuticals Industry
SWOT — 6
Croatia Political SWOT — 7
Croatia Economic SWOT — 7
Croatia Business Environment
SWOT — 8
Pharmaceutical Business Environment
Ratings — 9
Table: Emerging Europe -Regional Pharma
Business Environment Ratings for Q409 — 9
Limits Of
Potential Returns — 10
Risks To Realisation Of
Returns — 11
Croatia – Market
Summary — 12
Regulatory Regime — 13
Intellectual Property Regime — 14
Pricing
Regime — 15
Reimbursement Regime — 16
Recent Pricing And Reimbursement Developments — 18
OTC
Regulations — 18
Industry Trends And
Developments — 20
Epidemiology — 20
Table: Disease Burden In CEE — 21
Healthcare
Provision — 22
Healthcare
Expenditure — 22
Healthcare Debts — 23
Healthcare Reform — 24
Domestic Pharmaceutical
Industry — 25
Domestic Company
Activity — 26
Foreign Company
Activity — 28
Pharmaceutical
Retail — 28
Research And Development
Sector — 30
Clinical Trials — 30
Medical Devices — 31
Industry Forecast
Scenario — 32
Overall Market
Forecast — 32
Table: Croatia – Drug Expenditure
Indicators, Historical Data and Forecasts — 33
Key Growth
Factors – Industry — 34
Table: Croatia –
Health Expenditure Indicators, Historical Data and
Forecasts — 35
Key Growth Factors –
Macroeconomic — 36
Table: Croatia – Economic
Activity, 2006-2013 — 38
Prescription Market
Forecast — 39
Table: Croatia – Prescription Market
Indicators, Historical Data and Forecasts (HRKmn unless otherwise
stated) — 40
Patented Market
Forecast — 42
Table: Croatia – Patented Market
Indicators, Historical Data and Forecasts — 43
Generics
Market Forecast — 44
Table: Croatia – Generics
Market Indicators, Historical Data and Forecasts — 45
OTC
Market Forecast — 46
Table: Croatia – OTC Market
Indicators, Historical Data and Forecasts (HRKmn unless otherwise
stated) — 47
Pharmaceutical Trade
Forecast — 48
Table: Croatia – Pharmaceutical Trade
Indicators, Historical Data and Forecasts (US$mn) — 48
Other Healthcare Forecasts — 49
Table: Croatia –
Other Healthcare Indicators, Historical Data and
Forecasts — 49
Key Risks To BMI’s Forecast
Scenario — 50
Competitive
Landscape — 51
Table: Croatia – Top 10 Medicines by
Value Sales — 52
Table: Croatia - Top 10 Medicines by
Value Sales in Retail Outlets — 52
Company
Monitor — 53
International Company
Profiles — 53
GlaxoSmithKline — 53
Pfizer — 54
Sanofi-Aventis — 55
Novartis — 56
Merck & Co — 57
Krka — 58
Indigenous Company
Profiles — 60
Pliva — 60
Belupo — 63
Jadran Galenski Laboratorij
(JGL) — 66
Country Snapshot: Croatia Demographic
Data — 68
Section 1: Population — 68
Table: Demographic Indicators, 2005-2030 — 68
Table:
Rural/Urban Breakdown, 2005-2030 — 69
Section 2: Education
And Healthcare — 69
Table: Education,
2000-2003 — 69
Table: Vital Statistics,
2005-2030 — 69
Section 3: Labour Market And Spending
Power — 70
Table: Employment Indicators,
1999-2004 — 70
Table: Consumer Expenditure, 2000-2010
(US$) — 71
Table: Average Annual Wages,
2000-2010 — 71
BMI Forecast
Modelling — 72
How We Generate Our Pharmaceutical Industry
Forecasts — 72
Pharmaceutical Business Environment Ratings
Methodology — 73
Ratings Overview — 73
Table: Pharmaceutical Business Environment Indicators — 74
Weighting — 75
Table: Weighting Of
Components — 75
Sources — 75
| 
View Cart
